<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>PubTator</source><date>2020-12-04</date><key>BioC.key</key>
<document><id>27470968</id><passage><infon key="type">title</infon><offset>0</offset><text>PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.</text><annotation id="0"><infon key="NCBI Gene identifier">5133</infon><infon key="type">STARGENE</infon><location offset="0" length="4"/><text>PD-1</text></annotation><annotation id="1"><infon key="NCBI Gene identifier">60533</infon><infon key="type">STARGENE</infon><location offset="5" length="5"/><text>PD-L1</text></annotation></passage><passage><infon key="type">abstract</infon><offset>116</offset><text>PURPOSE: Tyrosine kinase inhibitors are effective in gastrointestinal stromal tumors (GISTs) but often are of transient benefit as resistance commonly develops. Immunotherapy, particularly blockade of the inhibitory receptor programmed death 1 (PD-1) or the ligand programmed death ligand 1 (PD-L1), has shown effectiveness in a variety of cancers. The functional effects of PD-1/PD-L1 blockade are unknown in GISTs. EXPERIMENTAL DESIGN: We analyzed tumor and matched blood samples from 85 patients with GISTs and determined the expression of immune checkpoint molecules using flow cytometry. We investigated the combination of imatinib with PD-1/PD-L1 blockade in KitV558Delta/+ mice that develop GISTs. RESULTS: The inhibitory receptors PD-1, lymphocyte activation gene 3, and T-cell immunoglobulin mucin-3 were upregulated on tumor-infiltrating T cells compared with T cells from matched blood. PD-1 expression on T cells was highest in imatinib-treated human GISTs. Meanwhile, intratumoral PD-L1 expression was variable. In human GIST cell lines, treatment with imatinib abrogated the IFNgamma-induced upregulation of PD-L1 via STAT1 inhibition. In KitV558Delta/+ mice, imatinib downregulated IFNgamma-related genes and reduced PD-L1 expression on tumor cells. PD-1 and PD-L1 blockade in vivo each had no efficacy alone but enhanced the antitumor effects of imatinib by increasing T-cell effector function in the presence of KIT and IDO inhibition. CONCLUSIONS: PD-1/PD-L1 blockade is a promising strategy to improve the effects of targeted therapy in GISTs. Collectively, our results provide the rationale to combine these agents in human GISTs. Clin Cancer Res; 23(2); 454-65.  2016 AACR.</text><annotation id="2"><infon key="code">333</infon><infon key="NCBI Gene identifier">1956</infon><infon key="type">Gene</infon><location offset="125" length="15"/><text>Tyrosine kinase</text></annotation><annotation id="3"><infon key="code">000</infon><infon key="NCBI Gene identifier">5133</infon><infon key="type">STARGENE</infon><location offset="341" length="18"/><text>programmed death 1</text></annotation><annotation id="4"><infon key="code">000</infon><infon key="NCBI Gene identifier">5133</infon><infon key="type">STARGENE</infon><location offset="361" length="4"/><text>PD-1</text></annotation><annotation id="5"><infon key="code">000</infon><infon key="NCBI Gene identifier">29126</infon><infon key="type">STARGENE</infon><location offset="381" length="25"/><text>programmed death ligand 1</text></annotation><annotation id="6"><infon key="code">000</infon><infon key="NCBI Gene identifier">29126</infon><infon key="type">STARGENE</infon><location offset="408" length="5"/><text>PD-L1</text></annotation><annotation id="7"><infon key="code">000</infon><infon key="NCBI Gene identifier">5133</infon><infon key="type">STARGENE</infon><location offset="491" length="4"/><text>PD-1</text></annotation><annotation id="8"><infon key="code">000</infon><infon key="NCBI Gene identifier">29126</infon><infon key="type">STARGENE</infon><location offset="496" length="5"/><text>PD-L1</text></annotation><annotation id="9"><infon key="NCBI Gene identifier">18566</infon><infon key="type">STARGENE</infon><location offset="758" length="4"/><text>PD-1</text></annotation><annotation id="10"><infon key="NCBI Gene identifier">60533</infon><infon key="type">STARGENE</infon><location offset="763" length="5"/><text>PD-L1</text></annotation><annotation id="11"><infon key="NCBI Gene identifier">16590</infon><infon key="type">Gene</infon><location offset="781" length="3"/><text>Kit</text></annotation><annotation id="12"><infon key="NCBI Gene identifier">5133</infon><infon key="type">STARGENE</infon><location offset="855" length="4"/><text>PD-1</text></annotation><annotation id="13"><infon key="NCBI Gene identifier">3902</infon><infon key="type">Gene</infon><location offset="861" length="28"/><text>lymphocyte activation gene 3</text></annotation><annotation id="14"><infon key="NCBI Gene identifier">84868</infon><infon key="type">Gene</infon><location offset="895" length="29"/><text>T-cell immunoglobulin mucin-3</text></annotation><annotation id="15"><infon key="NCBI Gene identifier">5133</infon><infon key="type">STARGENE</infon><location offset="1014" length="4"/><text>PD-1</text></annotation><annotation id="16"><infon key="NCBI Gene identifier">29126</infon><infon key="type">STARGENE</infon><location offset="1110" length="5"/><text>PD-L1</text></annotation><annotation id="17"><infon key="code">000</infon><infon key="NCBI Gene identifier">3458</infon><infon key="type">Gene</infon><location offset="1205" length="8"/><text>IFNgamma</text></annotation><annotation id="18"><infon key="NCBI Gene identifier">29126</infon><infon key="type">STARGENE</infon><location offset="1238" length="5"/><text>PD-L1</text></annotation><annotation id="19"><infon key="NCBI Gene identifier">6772</infon><infon key="type">Gene</infon><location offset="1248" length="5"/><text>STAT1</text></annotation><annotation id="20"><infon key="NCBI Gene identifier">16590</infon><infon key="type">Gene</infon><location offset="1269" length="3"/><text>Kit</text></annotation><annotation id="21"><infon key="code">000</infon><infon key="NCBI Gene identifier">15978</infon><infon key="type">Gene</infon><location offset="1313" length="8"/><text>IFNgamma</text></annotation><annotation id="22"><infon key="NCBI Gene identifier">60533</infon><infon key="type">STARGENE</infon><location offset="1348" length="5"/><text>PD-L1</text></annotation><annotation id="23"><infon key="NCBI Gene identifier">18566</infon><infon key="type">STARGENE</infon><location offset="1381" length="4"/><text>PD-1</text></annotation><annotation id="24"><infon key="NCBI Gene identifier">60533</infon><infon key="type">STARGENE</infon><location offset="1390" length="5"/><text>PD-L1</text></annotation><annotation id="25"><infon key="NCBI Gene identifier">16590</infon><infon key="type">Gene</infon><location offset="1545" length="3"/><text>KIT</text></annotation><annotation id="26"><infon key="NCBI Gene identifier">15930</infon><infon key="type">Gene</infon><location offset="1553" length="3"/><text>IDO</text></annotation><annotation id="27"><infon key="NCBI Gene identifier">5133</infon><infon key="type">STARGENE</infon><location offset="1582" length="4"/><text>PD-1</text></annotation><annotation id="28"><infon key="NCBI Gene identifier">29126</infon><infon key="type">STARGENE</infon><location offset="1587" length="5"/><text>PD-L1</text></annotation></passage></document>
</collection>
